ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2026
Beta-lactam antibiotics under light: optical and photochemical characterization.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibiotics (ATBs) remain a cornerstone in the treatment of bacterial infections, yet clinical practice increasingly incorporates photonic therapies such as photobiomodulation (PBM) and photodynamic therapy (PDT). These modalities, widely used in infectious and inflammatory conditions, are frequently administered concomitantly with ATBs. However, the potential photochemical interactions between β-lactam ATBs and light-based therapies remain poorly understood, raising questions about efficacy and safety in combined treatment settings. In this study, we characterized the optical and photochemical properties of representative β-lactam ATBs, including penicillins (amoxicillin, oxacillin), cephalosporins (cephalothin, cefazolin, ceftazidime, ceftriaxone, cefuroxime), and a carbapenem (meropenem). Using diffuse transmittance and reflectance spectroscopy, we calculated absorption and scattering coefficients via the Kubelka-Munk function. Reactive oxygen species (ROS) generation was assessed under direct blue light (460 nm) illumination and red light exposure in the presence of methylene blue (MB), a clinically employed photosensitizer. Cephalosporins demonstrated significant ROS generation under blue light, whereas penicillins and meropenem did not. In PDT-like conditions, meropenem enhanced MB-mediated ROS production and promoted MB photobleaching, suggesting potentiation of PDT effects. In contrast, penicillins suppressed MB-driven ROS generation, potentially limiting PDT efficacy. Cephalosporins showed heterogeneous effects, either enhancing, reducing, or leaving MB-induced ROS unchanged. These findings indicate that β-lactam ATBs exert distinct photobiological behaviors with potential clinical consequences. Cephalosporins may act as intrinsic photosensitizers, meropenem may potentiate PDT, and penicillins may attenuate phototherapy efficacy. Recognizing such interactions is critical to optimizing combined ATB-phototherapy regimens and avoiding unintended antagonism or toxicity in clinical practice.
Indexed as
Identifiers
41396472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.